This collaboration will harness Charles River's expertise in plasmid DNA production to support Axovia Therapeutics' mission of developing potentially transformative therapies for ciliopathies. Axovia believe this partnership will play a crucial role in accelerating our efforts to bring impactful therapies to patients in need.
